Promising HAE pill trial cut short by low enrollment
NCT ID NCT05055258
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tested three doses of an experimental oral drug, KVD824, to see if it could prevent swelling attacks in people with hereditary angioedema (HAE) types I and II. The trial was stopped early because not enough volunteers enrolled, so results are limited. The drug works by blocking a protein involved in triggering attacks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOEDEMA, HEREDITARY, TYPES I AND II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KalVista Investigative Site
Birmingham, Alabama, 35294, United States
-
KalVista Investigative Site
Scottsdale, Arizona, 85251, United States
-
KalVista Investigative Site
La Jolla, California, 92093, United States
-
KalVista Investigative Site
Santa Monica, California, 90404, United States
-
KalVista Investigative Site
Centennial, Colorado, 80112, United States
-
KalVista Investigative Site
Tampa, Florida, 33620, United States
-
KalVista Investigative Site
Chevy Chase, Maryland, 20815, United States
-
KalVista Investigative Site
Boston, Massachusetts, 02114, United States
-
KalVista Investigative Site
St Louis, Missouri, 63110, United States
-
KalVista Investigative Site
Cincinnati, Ohio, 45231, United States
-
KalVista Investigative Site
Hershey, Pennsylvania, 17033, United States
-
KalVista Investigative Site
Dallas, Texas, 75390, United States
-
KalVista Investigative Site
Spokane, Washington, 99204, United States
-
KalVista Investigative Site
Campbelltown, New South Wales, Australia
-
KalVista Investigative Site
Sofia, Bulgaria
-
KalVista Investigative Site
North York, Ontario, Canada
-
KalVista Investigative Site
Brno, Czechia
-
KalVista Investigative Site
Prague, Czechia
-
KalVista Investigative Site
Grenoble, France
-
KalVista Investigative Site
Paris, France
-
KalVista Investigative Site
Mainz, Rhineland-Palatinate, Germany
-
KalVista Investigative Site
Berlin, Germany
-
KalVista Investigative Site
Frankfurt am Main, Germany
-
KalVista Investigative Site
Budapest, Hungary
-
KalVista Investigative Site
Milan, Italy
-
KalVista Investigative Site
Padova, Italy
-
KalVista Investigative Site
Grafton, Auckland, New Zealand
-
KalVista Investigative Site
Skopje, North Macedonia
-
KalVista Investigative Site
San Juan, Puerto Rico
-
KalVista Investigative Site
Birmingham, United Kingdom
-
KalVista Investigative Site
Leeds, United Kingdom
-
KalVista Investigative Site
London, United Kingdom
-
KalVista Investigative Site
Newcastle upon Tyne, United Kingdom
Conditions
Explore the condition pages connected to this study.